Overview of Primary Treatment Strategies and Response Status Before HDC in 37 Children With B-NHL and Poor Response to First-Line Chemotherapy
| First-Line Protocol . | No. of Patients . | Response Status Before HDC . | Second-Line CCT . | Type of Second-Line CCT . | Third-Line CCT . | Type of . | Local Irradiation . | Surgery . |
|---|---|---|---|---|---|---|---|---|
| . | . | . | (yes/no) . | . | (yes/no) . | Third-Line CCT . | . | . |
| COPAD | 9 | 4 CR | 2/2 | COPADM | — | — | 2 | |
| MTX/Ara-C | ||||||||
| 1 PR | 1/0 | COPADM | 1/0 | VP16-CDDP | — | — | ||
| 4 PRD | 3/1 | COPADM/VP16-CDDP | — | — | — | |||
| LMB 81/84 | 19 | 4 CR | 1/3 | VP16/CDDP | — | 3 | 3 | |
| 11 PR | 6/5 | CYVE | — | 1 | 11 | |||
| 4 PRD | 2/2 | CYVE | 2/0 | VP16-CDDP | 2 | — | ||
| LMB 86/89 | 4 | 4 PR | 1/3 | CYVE | — | — | 2 | |
| Others | 4 | 1 CR | 0/1 | — | — | 1 | — | |
| 2 PR | 1/1 | CYVE | — | — | 1 | |||
| 1 PRD | 1/0 | COPADM | — | — | — |
| First-Line Protocol . | No. of Patients . | Response Status Before HDC . | Second-Line CCT . | Type of Second-Line CCT . | Third-Line CCT . | Type of . | Local Irradiation . | Surgery . |
|---|---|---|---|---|---|---|---|---|
| . | . | . | (yes/no) . | . | (yes/no) . | Third-Line CCT . | . | . |
| COPAD | 9 | 4 CR | 2/2 | COPADM | — | — | 2 | |
| MTX/Ara-C | ||||||||
| 1 PR | 1/0 | COPADM | 1/0 | VP16-CDDP | — | — | ||
| 4 PRD | 3/1 | COPADM/VP16-CDDP | — | — | — | |||
| LMB 81/84 | 19 | 4 CR | 1/3 | VP16/CDDP | — | 3 | 3 | |
| 11 PR | 6/5 | CYVE | — | 1 | 11 | |||
| 4 PRD | 2/2 | CYVE | 2/0 | VP16-CDDP | 2 | — | ||
| LMB 86/89 | 4 | 4 PR | 1/3 | CYVE | — | — | 2 | |
| Others | 4 | 1 CR | 0/1 | — | — | 1 | — | |
| 2 PR | 1/1 | CYVE | — | — | 1 | |||
| 1 PRD | 1/0 | COPADM | — | — | — |
Abbreviations: COPAD protocol, cyclophosphamide, vincristine, prednisone, and doxorubicin; LMB81 protocol, consecutive cycles of the COPAD combination plus high-dose MTX (3 g/m2) and intrathecal injections of MTX and Ara-C; LMB84 protocol, consecutive cycles of the COPAD combination plus high-dose MTX (3 g/m2) and continuous intravenous Ara-C infusion (500 mg/m2) intrathecal injections of MTX and Ara-C; LMB 86/89 (high-risk arm) protocols, high-dose MTX (12 g/m2), intrathecal triple therapy and consolidation with high-dose Ara-C, VP16, and cranial irradiation; CYVE, high-dose Ara-C and VP16; MIME, methylgag, ifosfamide, MTX, and VP16.